Novo Nordisk
1H Revenues: $6.2 billion (+17%)
1H Earnings: $1.7 billion (+22%)
Comments: Modern insulin sales increased 20% to $2.8 billion, with sales of Victoza up 82% to $717 million. Biopharmaceutical segment sales were $1.4 billion, up 6%. Sales in North America increased by 29%. International sales increased 19%.
Financial Report: Novo Nordisk
Published August 9, 2012
Related Searches:
Financial Reports
•
blog comments powered by Disqus
